pharmanucleus1

[pharmanucleus1]

Asthma Treatment Market: Innovations for Breathing Relief

Asthma Treatment Market

Asthma Treatment Market is segmented By Treatment (Long-Term Control Medications,Quick-Relief Medications,Route Of Administration (Injectable,Oral,Inhaled), By Distribution Channel (Hospital Pharmacies,Retail Pharmacies & Drug Stores,Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, And Africa) – Share, Size, Outlook, And Opportunity Analysis, 2023-2030.

Click here for full report:

https://www.pharmanucleus.com/reports/asthma-treatment-market

KEY MARKET INSIGHTS

The global asthma treatment market size stood at USD 18.08 billion in 2019 and is projected to reach USD 26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period.

In today's healthcare environment, respiratory health is critical, particularly because respiratory disorders such as asthma are among the major causes of mortality and disability globally. According to the World Health Organisation (WHO) study on "The Global Impact of Respiratory Disease" issued in 2017, an estimated 334 million people suffer with asthma. Individuals with moderate to severe asthma were at a higher risk of contracting acute respiratory illness during the 2019-2020 coronavirus pandemic, according to the Centres for illness Control and Prevention (CDC). Numerous clinical studies are being done by industry participants to explore novel asthma medicines, particularly in light of the 2019-2020 coronavirus pandemic.

MARKET TRENDS

Increasing R&D for Advanced Asthma Therapeutics to Augment Market Growth

One of the significant industry trends in this market is the strong and vigorous R&D being conducted by leading market players for the development of enhanced asthma treatments. Because asthma is a chronic condition that affects a large number of people globally, including children, a number of major pharmaceutical firms are active in the development of asthma medications. This engagement involves the availability of multiple promising asthma therapy candidates in various phases of clinical studies. For example, Novartis revealed good findings from the phase III IRIDIUM trial of the inhaled combination QVM149 in patients with uncontrolled asthma in September 2019. This asthma therapy medication candidate allows patients to better regulate their asthma symptoms, resulting in a significant improvement in the patients' health.

Click here for free sample report:

https://www.pharmanucleus.com/request-sample/1194

MARKET DRIVERS

Increasing Prevalence of Asthma Worldwide is Anticipated to Fuel Demand for Better Asthma Treatment Outcomes

One of the critical market drivers of this market is the increasing prevalence of chronic respiratory diseases such as asthma globally. Asthma is considered to be the most common chronic disease worldwide, and this has particularly driven the need for advanced therapeutics for asthma treatment. Asthma, if especially present in the individual in the severe form, is a severely debilitating disease and thus requires the administration of treatment drugs for asthma. Thus, the increasing need for a better quality of life for the patients undergoing asthma treatment is also expected to drive the market growth. According to the American Academy of Allergy, Asthma & Immunology (AAAAI), in the United States in 2016, it was estimated that approximately 8.3% of children in the U.S. had asthma. The introduction of low cost and effective therapeutics is anticipated to drive the growth of the global market during the forecast period.

Another major factor is the growing need for improved clinical and therapeutic asthma treatments in light of the 2019-2020 coronavirus pandemic. Asthma therapy is in high demand since both the COVID-19 and asthma are respiratory ailments. This is partly because, because asthma is the most prevalent chronic condition, with a big patient population pool, the COVID-19 is expected to aggravate asthma symptoms in those who suffer from it, prompting the need for effective asthma therapy. The Centers for Disease Control and Prevention (CDC), during the 2019-2020 coronavirus pandemic has issued special guidelines for patients undergoing treatment for asthma and also advocated greater precaution for asthma patients. This is projected to spur the demand for advanced asthma treatment drugs which, in turn, will favor growth of this market.

Click here for full report:

https://www.pharmanucleus.com/reports/asthma-treatment-market

Increasing Number of Product Launches to Drive the Asthma Treatment Market Growth

In light of the 2019-2020 coronavirus pandemic, there is a greater demand for various types of treatment drugs for asthma, because both the respiratory illnesses are closely linked. The increasing demand for asthma treatment has led to the U.S. FDA issuing priority regulatory approvals to a number of asthma drugs, which includes key generic equivalents. For instance, in April 2020, the U.S. FDA provided regulatory approval to Cipla’s key generic asthma treatment drug, and a similar generic equivalent from Lupin is also anticipated to gain regulatory approvals. Such developments and trends are further leading to the increasing product launches of significant capability from prominent companies. The increasing product launches are further undertaken in order to ensure that there are no significant asthma medications shortages. The above factors combined with the need for efficient therapeutics is further projected to fuel the demand for these drugs and boost the global market growth. 

MARKET RESTRAINT

High Cost of Asthma Medications Coupled with Underdiagnosis of Asthma to Restrain Market Growth

Despite the rising incidence of asthma worldwide, particularly in both emerging markets such as Asia and developed markets such as North America, several impediments to the adoption of these therapies exist. Higher prices associated with asthma inhalers, which are frequently regarded the primary therapy for Asthma, are one of the major reasons constraining market development. For example, the price of Advair, a vital asthma medicine, has grown from US$ 316 in 2013 to US$ 496 in 2018, a 56.0% increase. Aside from high drug prices, another significant element has inhibited market growth: asthma underdiagnosis.

Underdiagnosis of asthma results in inferior clinical outcomes for patients who are unable to use the right asthma medicines as a treatment for their medical condition. Such obstacles are expected to considerably stifle market expansion.

SEGMENTATION

By Treatment Analysis

Long-Term Control Medications Dominated the Global Market

The global market is divided into two categories based on treatment: long-term control drugs and quick-relief treatments. Because asthma is considered a chronic condition, the primary therapy for such problems is frequently long-term drugs for asthma control and management. As a result, long-term control drugs dominated the global market in 2019. Some of the important pharmaceuticals in this area include Advair, Qvar, and Symbicort, which have contributed to the segment's supremacy in the worldwide market. Inhaled and combination corticosteroids, leukotriene modifiers, anticholinergics, and immunomodulators are some of the important medication classes in this category.

The category of quick-relief drugs is expected to be the second-largest. This section's pharmacological classes include short-acting beta-agonists (SABAs), and the drugs in this segment give immediate relief of asthma symptoms by relaxing airway muscles. Albuterol sulphate is one of the most important asthma treatments in this sector.

Click here for free sample report:

https://www.pharmanucleus.com/request-sample/1194

By Route of Administration Analysis

Large Number of Products Administered Through Inhalation Anticipated to Aid in the Dominance of the Segment

The market is divided into injectable, oral, and inhalation routes of delivery. Because a considerable number of asthma medicines are provided in this manner, the inhalation sector is expected to dominate the method of administration segment. Some of the major products are Pulmicort and Qvar, and this sector is expected to maintain control of its market share over the projected period, resulting in the segment's dominance in the worldwide market. The injectable sector is expected to expand during the forecast period because a number of immunomodulators, an important medication class, are expected to rise during the forecast period and are injected subcutaneously.

The oral section is expected to increase slowly throughout the projection period. The rising influx of generic counterparts, as well as the increased absorption of immunomodulators, are likely to constrain sector growth throughout the projection period.

By Distribution Channel Analysis

Higher Administration of Therapeutics at Hospital Pharmacies to Enable Dominance of the Segment

The market is divided into three distribution channels: hospital pharmacies, retail pharmacies & pharmacy shops, and internet pharmacies. One of the primary reasons for hospital pharmacies' dominance is that the medicines used in asthma therapy are typically only available in hospital settings with educated medical experts. This allows for adequate adherence to treatment standards as well as the appropriate and safe delivery of important medications, some of which need subcutaneous injections. Asthma symptoms can frequently be effectively controlled with correct and suitable medication.

Retail pharmacies and drug stores are expected to command the second largest market share, owing to the refilling of asthma prescriptions such as inhaled corticosteroids, which can be done at these locations, being one of the major factors driving this segment's growth during the forecast period.

Because of the simplicity and convenience provided to patients in terms of purchasing crucial asthma drugs, internet pharmacies are expected to develop at the fastest CAGR.

#asthma treatment #breathing relief #respiratory health #innovative solutions #lung condition management

[pharmanucleus1]

Antimicrobial Susceptibility Market: Precision in Pathogen Control

Antimicrobial Susceptibility Testing Market

The worldwide antimicrobial susceptibility testing market is expected to increase at a 5.5% CAGR from 2022 to 2027, from an anticipated value of US$3.6 billion in 2022 to US$4.7 billion in 2027. The Antimicrobial Susceptibility Testing (AST) Technology Market is expanding due to factors such as rising infectious illness prevalence, increased antibiotic resistance, and favourable government measures to minimise infectious disease burden. Antibiotic susceptibility testing is becoming more popular due to the rising prevalence of certain illnesses, such as bloodstream infections and pneumonia caused by E. coli, K. pneumonia, and P. aeruginosa, among others.

Click here for full report:

https://www.pharmanucleus.com/reports/antimicrobial-susceptibility-market

Antimicrobial Susceptibility Testing Market Dynamics

Drivers: Emergence of multidrug resistance due to drug abuse

The rise of drug resistance poses a significant threat to global health, particularly in the context of antibiotics. Antibiotics are becoming less effective as drug-resistant strains of bacteria spread worldwide. This has profound implications for disease treatment, as it makes infections more difficult to treat and ultimately increases mortality rates.

The World Health Organization (WHO) has identified drug-resistant pathogens, such as carbapenem-resistant gram-negative bacteria, as a major concern. Urgent development of new drugs is necessary to combat these infections effectively. However, without a fundamental change in the way antibiotics are used, the effectiveness of these new treatments may be compromised.

Misuse and overuse of antibiotics contribute to the development of drug resistance. Factors such as inappropriate prescribing, improper self-medication, and the use of antibiotics in livestock and agriculture all contribute to the problem. These practices create an environment where bacteria can adapt and develop resistance mechanisms, rendering antibiotics less effective over time.

To preserve the efficacy of antibiotics, it is crucial to promote responsible antibiotic use. This includes raising awareness among healthcare providers and the general public about appropriate antibiotic prescribing and the importance of completing prescribed courses of treatment. Additionally, robust regulations and surveillance systems are needed to monitor antibiotic use in various sectors, including healthcare, agriculture, and veterinary medicine.

Efforts to develop new antibiotics should be complemented by strategies to optimize their use, such as antibiotic stewardship programs and infection prevention and control measures. Research into alternative treatment options, such as phage therapy and immunotherapies, is also essential to diversify the arsenal against drug-resistant bacteria.

Opportunities: Growth opportunities in emerging market

The antimicrobial susceptibility testing market players are poised with significant opportunities in developing countries such as APAC (Asia-Pacific), India, China, and Japan. These countries are experiencing a notable growth in the antimicrobial susceptibility testing market, driven by several factors.

Firstly, the booming medical tourism industry in these regions attracts a large influx of patients seeking healthcare services, including diagnostics. This surge in medical tourism creates a demand for antimicrobial susceptibility testing as part of the diagnostic process.

Secondly, the adult population (over 20 years old) is growing in these countries, leading to a higher prevalence of infectious diseases. As a result, there is an increased need for accurate and timely antimicrobial susceptibility testing to guide appropriate treatment decisions.

Additionally, the increasing use of drugs in these regions contributes to the demand for antimicrobial susceptibility testing. With a growing population and expanding healthcare access, the requirement for testing to guide optimal drug selection and treatment outcomes becomes crucial.

Moreover, these countries possess a strong and skilled workforce that is well-versed in high technology. This skilled workforce plays a vital role in the successful implementation and operation of advanced antimicrobial susceptibility testing technologies, ensuring accurate and reliable results.

Furthermore, the relatively lax import/export laws in these regions provide an advantageous environment for market players to expand their brands and offerings. The underdeveloped nature of certain areas in these countries presents opportunities for companies to introduce and establish their technologies, filling gaps in the market and addressing unmet needs. 

The growing number of technicians and their desire to learn and adopt new technologies further contribute to the development and updating of antimicrobial susceptibility testing capabilities in these regions, fostering innovation and advancements in the field.

Click here for full report:

https://www.pharmanucleus.com/reports/antimicrobial-susceptibility-market

Challenges: Complex Regulatory Frameworks

One of the major challenges in antibiotic susceptibility testing is the time gap between establishing clinical thresholds, obtaining regulatory approval for innovative antimicrobial treatments, and bringing those drugs to market. The process of gaining approval for new drugs involves stringent guidelines set by regulatory bodies like the FDA, which can result in significant delays.

The lack of established clinical thresholds for certain drugs further complicates the use of products aimed at increasing the susceptibility of microorganisms. Clinical thresholds are important benchmarks used to determine the effectiveness and appropriate usage of antimicrobial therapies. In some cases, such as invasive mold infections other than Aspergillus, the efficacy of antifungal therapy cannot be accurately assessed without the availability of specific clinical thresholds.

This time lag and absence of clinical thresholds can hinder the timely utilization of innovative antimicrobial treatments. It delays access to potentially life-saving therapies and limits healthcare professionals' ability to make informed decisions regarding treatment choices. The gap between setting clinical thresholds, regulatory approval, and market availability needs to be addressed to ensure that effective antimicrobial treatments reach patients in a timely manner and contribute to the fight against drug-resistant microorganisms.

Click here for request free sample:

https://www.pharmanucleus.com/request-sample/1193

Restraints: High Cost of automated Laboratory Instruments

Automated equipment for antimicrobial laboratories is quite expensive and offers premium features and functionality. The introduction of automated AST systems shortens incubation and detection times. Another barrier to this market is the high maintenance cost of  these devices, which come with the latest software and require regular maintenance.

#antimicrobial susceptibility #pathogen control #infection management #precision medicine #microbial resistance solutions

[pharmanucleus1]

Airway Management Devices Market: Revolutionizing Patient Care

According to a recent study report, the airway management devices market is predicted to generate $1.8 billion in revenue in 2022, growing to $2.4 billion by 2028. This equates to a compound annual growth rate (CAGR) of 5.6% between 2022 and 2028. The research looks at market purchasing patterns, price analysis, patent valuation, conference and webinar materials, and industry trends. Several factors are propelling market growth, including a rise in surgical procedures, an increase in the prevalence of chronic respiratory illnesses such as asthma and COPD, and an increase in demand for airway management devices in emerging economies.

Click here for full report:

https://www.pharmanucleus.com/reports/airway-management-devices-market

Airway Management Devices Market Dynamic

DRIVER: Rising incidence of pre-term births globally

Preterm birth occurs when a baby is born before the full 37 weeks of pregnancy. Premature births have recently become more common on a global scale. Babies who have trouble breathing may benefit from mechanical ventilation. These infants may also have breathing difficulties, apnea, asthma, and other respiratory abnormalities. Taking these factors into consideration, the growing prevalence of pre-term neonates promotes demand for airway management equipment. Vendors are offering items that satisfy the needs of newborns and paediatric patients in order to address the need for products that come in a variety of sizes and forms for airway control.

Click here for free sample report:

https://www.pharmanucleus.com/request-sample/1192

Restraint: Lack of reimbursement policies across emerging countries

Pricey airway management devices are rarely frequently utilised in emerging nations due to poor reimbursement systems or a lack of public health insurance coverage. Individuals are pushed to spend money they don't have because of ineffective policies and a lack of support for universal health care, which has a negative impact on the financial status of the poor throughout developing countries. Such circumstances have made a country more vulnerable to the threat of chronic diseases. Due to the high out-of-pocket costs of healthcare, the restricted adoption of costly medical devices such as video laryngoscopes and advanced surgical methods in developing countries has become a key market constraint.

OPPORTUNITY: Rising growth potential in developing countries

Market participants may anticipate future development opportunities from growing economies such as China, India, and Brazil. The primary motivation for development is because China and India have massive target patient populations. China's one-child policy has resulted in a considerable decrease in working-age population while increasing the elderly population. Furthermore, Malaysia and India have become important medical tourism hubs. Surgical procedures in these impoverished countries are substantially less expensive than in wealthier countries like the United States, Germany, France, and the United Kingdom. As the number of procedures grows, more airway management and anaesthetic treatments will be necessary.

Click here for free sample report:

https://www.pharmanucleus.com/request-sample/1192

CHALLENGE: Dearth of skilled professionals

Advanced training is required for airway management procedures such as cricothyrotomy, tracheostomy, and endotracheal intubation. Due to a lack of knowledge regarding the optimal course of urgent treatment, the patient's health may deteriorate, the recovery period may prolong, and direct and indirect expenditures may rise. A scarcity of anesthesiologists and paramedics is a big concern for governments all over the world. The paucity of airway management equipment used in these surgeries has further impacted the efficacy and ability of healthcare facilities to provide surgical and emergency treatment.

Click here for full report:

https://www.pharmanucleus.com/reports/airway-management-devices-market

Airway Management Devices Ecosystem

The airway management devices market is dominated by players such Medtronic (Ireland), ICU Medical

#airway management devices #patient care innovations #healthcare efficiency #safety enhancement #medical devices market

[pharmanucleus1]

Acute Pancreatitis Market: Breakthrough Treatments, Insights

Market Overview:

The Acute Pancreatitis Market Size was valued at USD 5.5 billion in 2023 and is projected to grow from USD 5.8 Billion in 2023 to USD 8.2 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.90% during the forecast period (2023 - 2030). The major market driver fueling the expansion is the increased prevalence of gastrointestinal issues.

Click here for full report:

https://www.pharmanucleus.com/reports/acute-pancreatitis-market

Acute Pancreatitis Market Trends

Increase in the occurrence of acute pancreatitis to propel market growth

According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 275,000 Americans are hospitalized each year for acute pancreatitis (NIDDK). When the pancreas swells and becomes irritated, pancreatitis (swelling) results. It is not a widespread disease. The most common reasons are gallstones or excessive alcohol consumption. The disease can develop gradually over time or come on suddenly, causing serious injury. Treatment for pancreatitis may include intravenous (IV) fluids, painkillers, and other medications. Rising occurrence of acute pancreatitis globally will be a key factor in increasing the market growth rate. Gallstones and excessive alcohol consumption, especially in young people, are the main causes of acute pancreatitis. Gallstones are the most common cause of AP, accounting for 28-38% of cases, and alcohol consumption is the second most common cause, accounting for 19-41% of cases, according to an article published in the World Journal of Clinical Cases. - Assessment and management of acute pancreatitis in 2019. The likelihood of developing acute pancreatitis increases as the number of people with gallstones increases. Thus, this factor is driving the CAGR of the market.

Additionally, there is growing global interest in understanding the impact of chronic comorbidities on people with acute pancreatitis. Recent research published in BioMed Hub in November 2021 revealed a correlation between gastrointestinal symptoms in the early stages of acute pancreatitis and pre-existing conditions such as metabolic syndrome, obesity and diabetes mellitus. Another PLOS One article from June 2021 points out that obesity is an important public health problem in France, as it increases the likelihood of developing chronic diseases such as diabetes, hypertension and other conditions with psychological and serious social. The increasing prevalence of obesity and its association with excessive eating habits also increases the risk of pancreatitis, contributing to the growth of this market segment. As a result, the acute pancreatitis market is expected to grow steadily throughout the forecast period, driven by factors such as rising prevalence of obesity and growing use of intravenous therapy.

However, the sector will increase as the elderly population grows and government awareness efforts are implemented. Furthermore, changing consumer lifestyles and increasing government-welcoming policies will propel market growth. An growth in the number of R&D activities is another factor driving the market's expansion. As a consequence, this aspect is likely to increase acute pancreatitis market revenue globally.

Click here for request free sample:

https://www.pharmanucleus.com/request-sample/1191

Acute Pancreatitis Market Segment Insights:

Acute Pancreatitis Cause Insights

Gallstones, alcohol, and other factors are among the causes of Acute Pancreatitis Market segmentation. According to Acute Pancreatitis Market statistics, the gallstones category held the most share in 2023. Acute pancreatitis is becoming more common over the world, as are gallstones. Gallstones cause around 40% of instances of acute pancreatitis. Gallstones afflict around 20 million people in the United States. Approximately 300,000 cholecystectomies are done on these individuals each year.

Acute Pancreatitis Treatment Insights

The therapy segmentation of the Acute Pancreatitis Market covers intravenous fluid, nutritional assistance, analgesics, endoscopic retrograde cholangiopancreatography (ERCP), and others. The intravenous fluid segment dominated market growth in 2023 and is expected to be the fastest-growing segment during the forecast period, 2023-2030, owing to factors such as the increased prevalence of acute pancreatitis, gallstones, and obesity in the population, as well as the risk factors associated with them. Acute pancreatitis is connected with dehydration and extreme fluid loss, which can be lethal and end in the patient's death. Intravenous fluid supply keeps the body hydrated, ensuring adequate blood flow to the other organs.

Acute Pancreatitis Diagnosis Insights

Based on diagnosis, the Acute Pancreatitis Market data covers imaging tests and laboratory testing. The laboratory testing category led the acute pancreatitis market revenue in 2023 and is expected to increase at the fastest rate during the forecast period, 2023-2030. Amylase and lipase are important pancreatic enzymes that may be detected through laboratory testing. The following may cause blood to gush. Other blood tests can be performed to detect gallbladder obstruction or injury.

Click here for full report:

https://www.pharmanucleus.com/reports/acute-pancreatitis-market

Acute Pancreatitis End-User Insights

End-users in the worldwide acute pancreatitis sector include hospitals, clinics, and others. Hospitals led the market in 2023 and are expected to be the fastest-growing sector throughout the forecast period, 2023-2030. The fact that hospitals are usually well-stocked and offer all services under one roof motivates patients with acute pancreatitis to seek treatment there. Another factor driving rising hospital visits is the increasing penetration of connected devices and equipment.

Click here for request free sample:

https://www.pharmanucleus.com/request-sample/1191

Acute Pancreatitis Regional Insights

According to the research, the market is classified into four regions: North America, Europe, Asia-Pacific, and the Rest of the World. The acute pancreatitis market in North America is expected to reach USD 2.5 billion in 2023, with a share of around 45.80%, and to grow at a rapid CAGR throughout the research period. Acute pancreatitis, obesity, and gallstones are all on the rise. These factors, together with a well-established healthcare infrastructure and high healthcare spending, are driving market expansion.

Significant countries included in the market study are the United States, Canada, Germany, France, the United Kingdom, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

The Asia Pacific acute pancreatitis market is the world's second biggest. The risk of pancreatic inflammation has increased as a result of growing obesity rates caused by changing lifestyles, which is projected to fuel market growth. Acute pancreatitis pharmaceutical and device-based therapies are expected to be in high demand, driving market development as R&D efforts in the area expand. Furthermore, the acute pancreatitis market in China was the largest, while the acute pancreatitis market in India was the fastest growing. Between 2023 and 2030, Europe's acute pancreatitis market is predicted to develop at the quickest CAGR. This is due to growing demand for certain drugs, and rising healthcare expenditures will accelerate market expansion in this area even more. The presence of significant competitors, as well as growing usage of newer technologies, will hasten market development in this business. Furthermore, the acute pancreatitis market in the United Kingdom was the largest, while the acute pancreatitis market in Germany was the fastest expanding.

#acute pancreatitis #market insights #breakthrough treatments #pancreatic disorder #treatment advancements

[pharmanucleus1]

Acupuncture Needles Market: Innovations Driving Growth | Expert Insights

Market Overview

The acupuncture needle market is expected to earn $240 million in sales in 2022 and $308 million by 2030, rising at a compound annual growth rate (CAGR) of 5.1% from 2023 to 2030. The new study report is an assessment of the market's key trends. Market buying patterns, pricing analysis, patent analysis, conference and webinar materials, and industry trends are all part of the most recent research study. The growing frequency of musculoskeletal pain, the number of injuries and procedures, and these trends are the key drivers of market expansion.

Acupuncture Needles Market Dynamics

Driver: Increasing prevalence of back, muscle, and neck pain

The outcomes of the study point to acupuncture as a viable therapy for persistent low back pain. Acupuncture points, according to Western practitioners, are places for stimulating connective tissue, muscles, and nerves. This stimulation is thought to augment the body's natural painkillers. Back pain affects up to 80% of Americans at some time in their life, according to Practical Pain Management. The treatment of low back pain (LBP) costs the US healthcare system at least USD 50 billion a year. Musculoskeletal problems affect 1.71 million individuals globally, according to the WHO (July 2022).

Click here for full report:

https://www.pharmanucleus.com/reports/acupuncture-needles-market

Growing demand for acupuncture

Acupuncture is becoming more popular at wellness centres, spas, and even beauty clinics. This diversification has resulted in the development of specialised acupuncture needles to meet the specific treatment requirements of different contexts.

Furthermore, the rise of e-commerce platforms has made acupuncture needles more widely available. A large selection of acupuncture needle alternatives are now available on online markets, bringing convenience and choice to both practitioners and consumers.

Restraint: Alternative methods and medicines

Alternative forms of stimulation are frequently employed over the acupuncture sites in place of needles. Among others, they include electromagnetic energy impulses, friction, heat (moxibustion), pressure (acupressure), and suction (cupping). Non-steroidal anti-inflammatory medicines (NSAIDs) are among the most often prescribed medications and have a variety of applications in the treatment of back and muscular pain. One major problem impeding the market's expansion is the use of complementary therapies and pharmaceuticals (such NSAIDs) to treat headaches, tight muscles, arthritis, and other aches and pains.

Opportunity: Use of acupuncture in rehabilitation of COPD patients

The outcomes of the study point to acupuncture as a viable therapy for persistent low back pain. Acupuncture points, according to Western practitioners, are places for stimulating connective tissue, muscles, and nerves. This stimulation is thought to augment the body's natural painkillers. Back pain affects up to 80% of Americans at some time in their life, according to Practical Pain Management. The treatment of low back pain (LBP) costs the US healthcare system at least USD 50 billion a year. Musculoskeletal problems affect 1.71 million individuals globally, according to the WHO (July 2022).

Challenge: Issues related to acupuncture standardization

There are a number of controversies or even issues that are misunderstood in the acupuncture and moxibustion industry as a result of the special characteristics of acupuncture therapy based on syndrome distinction. The growth of standardisation in various domains is being slowed down by these issues. According to a poll, 36.1% of respondents said that standardising moxibustion and acupuncture would limit the features of treatments based on the differentiation of syndromes and personalised care.

Click here for full report:

https://www.pharmanucleus.com/reports/acupuncture-needles-market

Disposable segment accounted for the largest share of the acupuncture needles market, by type

The market is divided into disposable and non-disposable needles based on kind. The market has a bigger percentage of disposable needles. The danger of disease transmission will be reduced by the use of disposable needles.

The non-disposable needles category is expected to increase at a modest rate in the acupuncture needles market throughout the forecast period. One of the biggest disadvantages of this product's material rate is the significant danger of disease transmission from one patient to another via non-disposable needles. Non-disposable needles, on the other hand, are extensively utilised in undeveloped and underdeveloped nations due to a lack of basic awareness about hygiene and Hospital Acquired Infections (HAIs) among patients and healthcare personnel.

Click here for request free sample:

https://www.pharmanucleus.com/request-sample/1190

Stainless-steel segment accounted for the largest share in the acupuncture needles market, by portability

The market is divided into stainless steel, gold, silver, plastic, and copper segments according on the handle material. Due to the lower price of stainless steel and the ease of availability, the stainless-steel handle needles category is expected to account for the greatest share over the projection period.

Clinics segment accounted for the largest share in the acupuncture needles market, by end user

Based on end users, the market is divided into hospitals and clinics. The clinical industry dominated the market. The rising number of private acupuncture clinics globally is the primary driver of this market segment's growth.

Online pharmacies segment accounted for the largest share in the acupuncture needles market, by distribution channel

The market has been divided into hospital, retail, and internet pharmacies based on the distribution route. The biggest market share, 49.0%, was held by the category of internet pharmacies. This is explained by elements like how simple it is to obtain a variety of goods in internet pharmacies.

Asia Pacific is the largest region for acupuncture needles market.

The global market is divided into four regions: North America, Europe, Asia Pacific and Rest of the World. Asia-Pacific held the largest market share, followed by Europe. The main driver of the market is the recent increase in the number of  local and international companies doing business in the Asia Pacific region.

Technology Trends

Acupuncture needle manufacturing has seen a spike in technological developments. Acupuncture needle manufacturers are actively investing in research and development to improve the design, materials, and manufacturing process. This has resulted in the development of needles with increased sharpness, reduced pain, and higher insertion efficiency.

Furthermore, the incorporation of nanotechnology has opened up new possibilities in the production of acupuncture needles. To improve the therapeutic effects of needle coatings, nanoparticles are being introduced. Such advancements are projected to transform the acupuncture needle industry, giving patients more effective and tailored treatment alternatives.

#acupuncture needles #market trends #holistic healing tools #growth factors #innovative products2

[pharmanucleus1]

Advanced Wound Care Market: Innovations Driving Healing Solutions

Advanced Wound Care Market Overview

The global advanced wound care market is estimated to be worth US$11.2 billion  in2023 and is expected to reach US$17.7 billion by 2030, growing at a CAGR of 9.4% over that period. Studying industry trends in the market is a new research report. The latest research  includes market buying patterns, pricing analysis, patent analysis, conference and webinar materials, and industry trends. Rising spending on chronic wounds, the prevalence of diseases and disorders that impede wound healing, and advances in technology are  key drivers of market growth.

Click here for full report:

Advanced Wound Care Market Dynamics

Driver: increasing number of surgical procedures across the globe

More operations are anticipated as surgical therapy becomes more available and cheap on a worldwide basis. Along with the development of chronic conditions and the expansion of surgical treatments, the frequency of associated surgical wounds and infections has grown. This will increase demand for better wound care products and debridement techniques in addition to cutting-edge therapies like NPWT.

Surgical procedures frequently cause tissue damage, extreme bleeding, or wound infections. Utilising cutting-edge wound care solutions, such as antibacterial honey wound dressings, has become a viable alternative to hasten the healing process by reducing wound bacterial colonisation and infection. More people are opting to employ sophisticated wound care treatments both before and after surgical operations as a result of a product's demonstrated advantages and the growing public awareness of their efficacy.

Click here for free sample request:

https://www.pharmanucleus.com/request-sample/1184

Restraint: High cost of advanced wound care products

The expensive cost of modern wound care products and chronic wound therapies may prevent their widespread use, particularly in low-income regions like Asia and the rest of the world. In these areas, patients and doctors choose affordable sophisticated wound care solutions. The preference for advanced wound care products is anticipated to rise over the next years, nevertheless, as more people become aware of the usefulness and necessity of these goods and as disposable incomes rise in many of these nations.

Opportunity: Growth potential of emerging economies

The markets for improved wound treatment in Asia Pacific and Latin America are less developed and offer greater market potential than those in Europe and North America. As a result, different players are concentrating on boosting their presence in certain areas. Major market participants have considerable development prospects in emerging economies including South Korea, Malaysia, Vietnam, South Korea, Africa, Israel, Saudi Arabia, and the United Arab Emirates. This may be as a result of relatively simple rules and restrictions, improvements in healthcare facilities including hospitals and clinics, an escalating patient population, particularly among the elderly, and rising healthcare costs.

Trend: Focus on expanding the current technologies and launching novel products.

The development of new products with absorbent, moisturizing and antibacterial properties is the result of research and development work to improve wound care products, including dressings. This in turn has led to a shift from simple to sophisticated dressings and an increased demand for products containing pharmacologically active ingredients. Market innovations are driven by the need to improve wound bed tissue condition and provide products that control wound healing.

Click here for full report:

The dressings segment accounted for the largest share of the advanced wound care market by product type.

The worldwide market is divided into topical agents, grafts and matrices, and dressings, devices, and accessories based on products. In 2023, the dressings sector held the biggest market share for advanced wound care, primarily as a result of growing patient education and an increase in HAI cases. This market is growing as a result of elements such the increasing incidence of venous ulcers, pressure ulcers, and diabetic ulcers.

The surgical and traumatic wounds segment accounted for the largest share of the advanced wound care market, by wound type.

The surgical and traumatic wounds, diabetic foot ulcers, pressure ulcers, venous leg ulcers, burns, and other wounds are the wound types into which the worldwide market is divided. Due to a rise in surgical operations done and an increase in the occurrence of SSIs, the surgical and traumatic wounds category will have the greatest share of the advanced wound care market in 2023.

Hospitals, ASCs, and wound care centers accounted for the largest share of the advanced wound care market by end user.

Hospitals, ASCs, and wound care facilities are one sector of the worldwide market, along with home care settings and other end users. The sector of hospitals, ASCs, and wound care facilities held the biggest market share for advanced wound care in 2023. The most significant market factors influencing the growth of this end-user category are the rise in hospital admissions for chronic wounds (such as pressure ulcers, diabetic foot ulcers, and venous leg ulcers) and the incidence of pressure ulcers and infections acquired in hospitals.

North America is the largest region of the advanced wound care market.

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the five primary regions of the worldwide market. The biggest market share is held by North America. The increasing number of acquisitions made by well-known North American firms is contributing in the expansion of the worldwide market in this industry. Demographic trends, increased patient awareness, and high market penetration of advanced wound care products are expected to fuel market expansion.

Pipeline Analysis

The advance wound care product pipeline encompasses a range of cutting-edge technologies and therapies designed to address various aspects of wound healing. These advancements are driven by a growing understanding of the complex biological processes involved in wound repair and an increasing demand for more effective treatments.NPWT is a widely adopted technique that involves applying negative pressure to a wound to promote healing.Cellular therapies involve the use of living cells to stimulate tissue repair and regeneration. Stem cell-based therapies, in particular, have shown promise in promoting wound healing by enhancing the production of growth factors and facilitating the regeneration of damaged tissues. Organogenesis Inc. and Osiris Therapeutics are at the forefront of developing cellular therapies for advanced wound care.

Competitive Landscape

As competition intensifies, companies are striving to differentiate themselves through research and development efforts. The future of advance wound care holds great promise for patients and healthcare providers alike, with the potential to transform the way wounds are managed and healed. Key market participants include Smith & Nephew, Mölnlycke Health Care, Acelity, Organogenesis Inc., and Osiris Therapeutics. These companies are investing heavily in research and development activities to bring innovative products to market and gain a competitive edge.

#advanced wound care #wound management #wound healing #innovative wound treatments #medical dressings #wound therapy techniques #wound care products #healing technologies1

[pharmanucleus1]

Global Osteoarthritis Market: Trends, Treatment, and Projections 2030

Report Summary 

In 2023, the worldwide osteoarthritis market was valued at USD 7.40 billion and is predicted to increase at an 8.5% CAGR during the forecast period 2023-2030. Both the introduction of analgesic drugs and the development of imaging diagnostics based on radiographic characteristics are stimulating market growth. Increased expenditure on healthcare infrastructure and expanding investments in research and development (R&D) efforts to bring novel diagnostics and biomarkers are also driving the market. 

Osteoarthritis (OA) is a group of disorders that affect the joints of the knees, hips, fingers, foot, back, shoulders, and neck. It is distinguished by the gradual degeneration of the cartilage in these joints. Stiffness, edoema, discomfort, persistent pain, loss of flexibility, a grating sensation, bone spurs, and sleep interruptions are all common symptoms of OA. 

Click here for full report:

Medical examination, X-rays, arthroscopy, joint fluid analysis, lab testing, and magnetic resonance imaging (MRI) scans can all be used to diagnose it. Depending on the outcomes, different medications and surgical techniques are prescribed to treat the disease's signs and symptoms. There are presently alternative medicines, physical therapy, and supporting devices on the market to relieve pain and improve joint function. 

Sedentary lifestyles, poor eating habits, and increasing weight and blood sugar levels make people more susceptible to develop OA. This is one of the primary driving drivers for market development, combined with an ageing population that is more susceptible to such disorders. Furthermore, the ease of access to MRI scans is a key growth-promoting factor. 

The COVID-19 outbreak is predicted to have only a minimal influence on the osteoarthritis therapy industry. Corticosteroids are being used less often in many medicine types. Although there is no evidence that corticosteroid injections significantly increase the risk of infection, the immune system may be less active for a few weeks following surgery. 

Even though the risk is extremely minimal, it should be taken into account before starting with the procedure. It should be noted that the World Health Organisation cautioned against the use of systemic corticosteroids in one of its guidelines for treating severe acute respiratory infections caused by coronavirus. 

Industry Dynamics 

Growth Drivers:  

Increased government investment on cell-based research, as well as the increasing use of opioids, are driving market expansion. Topical, oral, and analgesic medications are commonly used to treat osteoarthritis pain. Even if alternatives such as orthopaedic braces are used as part of a noninvasive approach to pain therapy, the adoption of pain pills for the disease is substantial due to the ease of administration and the cost of pain medications. Oral analgesics such as acetaminophen, NSAIDs, intra-articular medicines, and nutraceuticals are all common pain relievers. 

Personalised OA medications have also been proposed, which would represent a considerable advance in the diagnosis, therapy, and monitoring of disease severity in osteoarthritis patients. Simple measurement, appropriate levels of sensitivity and specificity, and test procedures available to and interpretable by clinicians are critical qualities of indicators of therapeutic relevance for a personalised approach to OA therapy. 

The use of biomarkers to identify individuals who are most likely to respond to specific medical therapies may increase treatment response rates and reduce the risk of exposing patients to medicines that are either unlikely to be effective or may cause harmful side effects from their treatment. Using a mix of unique biomarkers and baseline clinical parameters such as age and gender might be beneficial. 

Report Segmentation 

The market is primarily segmented based on treatment type, disease type, distribution channel, route of administration, and region. 

Click here for full report:

Knee Osteoarthritis segment is expected to witness fastest growth 

Personalised OA medications have also been proposed, which would represent a considerable advance in the diagnosis, therapy, and monitoring of disease severity in osteoarthritis patients. Simple measurement, appropriate levels of sensitivity and specificity, and test procedures available to and interpretable by clinicians are critical qualities of indicators of therapeutic relevance for a personalised approach to OA therapy. 

Furthermore, increased FDA approvals for the treatment of Knee OA are driving sector growth throughout the projection period. For example, Novartis announced in September 2021 that LNA043 had been granted fast-track designation by the US Food and Drug Administration (FDA) for knee osteoarthritis rehabilitation. 

Drugs targeted to treat severe diseases and address unmet medical needs can be created more swiftly and evaluated more quickly. LNA043, a possibly first-in-class disease-modifying treatment for osteoarthritis, is being developed. As a result, growing approvals for the treatment of knee OA drive market development throughout the projection period. 

Click here for free sample request:

Viscosupplementation segment industry accounted for the highest market share in 2021 

The rising prevalence of knee osteoarthritis is the key driver of this market's expansion. By injecting synovial fluid into the afflicted joints, which increases lubrication, viscosupplementation greatly lowers osteoarthritis discomfort. Furthermore, the market for viscosupplementation agents is expected to grow considerably over the forecast period due to the discovery of novel viscosupplementation agents and government efforts to boost research in the healthcare sector. 

Hospital Pharmacies are expected to hold the significant revenue share 

Hospital pharmacies retained the largest share of this market due to the large number of patients seeking treatment for osteoarthritis in hospitals and the vast assortment of osteoarthritis drugs available in these pharmacies. Another important advantage is the ease with which hospital pharmacy purchases may be reimbursed. 

The demand in North America is expected to witness significant growth 

A rise in the frequency of chronic diseases, an increase in the number of elderly people, and changes in people's lifestyles all contribute to the anticipation of market expansion in North America. As a result, the region is incorporating an increasing number of treatments and drugs. When compared to Canada and Mexico, the United States will command a substantial share of the North American market for osteoarthritis therapies. 

According to the CDC, osteoarthritis (OA), the most common kind of arthritis, is a severe chronic illness that affects 32.5 million individuals in the United States. OA is associated with ageing and is more common in those with other chronic conditions such as obesity, diabetes, and heart disease. However, 18.7 million people with OA, or more than half of them, are of working age (18 to 64 years). 

Furthermore, the availability of better treatment alternatives, government reimbursement guidelines, increased research and development activities in the creation of novel medicines, and the introduction of new therapies in the North American region are all expected to support market expansion in the region. 

Europe controlled the market for osteoarthritis therapies. The increased incidence of osteoarthritis, the ageing population, rising obesity rates in several European countries, and the growing number of sports- and accident-related injuries all contribute to this sector's large market share. 

#Global Osteoarthritis Market #osteoarthritis market #osteoarthritis treatment #global arthritis trends #osteoarthritis research #arthritis therapies #osteoarthritis prognosis #joint disease market #arthritis medication

[pharmanucleus1]

Global Opioid Use Disorder Market: Navigating the Insights and Innovations

Opioid Use Disorder Market 

KEY MARKET INSIGHTS 

The global Opioid Use Disorder (OUD) Market size was valued at USD 2.88 billion in 2023 and is projected to grow from USD 3.11 billion in 2022 to USD 5.64 billion by 2030, exhibiting a CAGR of 8.9% during the forecast period. Based on our analysis, the global market exhibited a decline of -10.1% in 2020 as compared to 2019. The global COVID-19 pandemic has been unprecedented and staggering, with opioid use disorder experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels.

Click here for full report:

https://www.pharmanucleus.com/reports/opioid-use-disorder 

Opioid Use condition (OUD) is a complicated condition characterised by the compelling use of opioid medicines, even if the individual wishes to quit or if the drugs significantly impact the person's mental and physical well-being. Buprenorphine, methadone, and naltrexone are the three pharmacological groups used in the pharmaceutical therapy. These are the only drug classes authorised by the FDA in the United States. 

The number of prescriptions for painkillers, which commonly contain opioids, is expected to climb as the worldwide population of individuals suffering from chronic pain grows. When these opioid-based medications are used and the patient's suffering is relieved, the patient's reliance or addiction to these drugs rises. This addiction is dangerous since an opioid overdose can result in death or lifelong impairment of a person's normal psychological and physiological functioning. 

Several governments, like the United States, have put laws in place to successfully handle this condition in order to lessen the risk. These legislative reforms, together with the increasing number of product releases by big corporations, are expected to have a positive influence on the sector. 

Click here for sample request:

https://www.pharmanucleus.com/request-sample/1182

POST COVID-19 IMPACT 

Reduced Demand for Medications amid COVID-19 Pandemic to Negatively Impact Market Growth? 

Depending on the demand, the COVID-19 pandemic had both beneficial and bad effects on pharmaceutical firms. Certain pharmaceutical items saw a drop in demand as fewer individuals risked visiting healthcare institutions such as hospitals and clinics. To stop the spread of the coronavirus epidemic, the different governments ordered strict national lockdowns. As a consequence, patient visits to hospitals decreased dramatically. Non-essential medical services cancellation or delay impacted market development as well. 

On the other side, there was a noticeable increase in patients having opioid overdoses and relapses in the OUD market. However, well-known firms in the field, such as Indivior, saw a significant drop in product sales during this time. Sales continued to fall sharply as a result of Covid-19-related problems. As a result, the worldwide market saw a negative trend during the epidemic. 

Click here for full report:

https://www.pharmanucleus.com/reports/opioid-use-disorder

LATEST TRENDS 

Increasing Consideration of Buprenorphine Patches as an Effective Treatment Mode to Propel Market Growth 

The industry has lately seen an increase in the demand for buprenorphine treatment patches. These patches are regarded as an effective medication for the treatment of opioid use disorders. The numerous advantages associated with transdermal patches, such as ease of medication delivery and decreased discomfort, are customary and self-administered. Furthermore, these transdermal patches may be a viable option for individuals requiring round-the-clock opioid medication for opioid use disorder. 

In 2019, for example, WellSpan Health collaborated with York Opioid Collaborative to conduct a clinical study to develop a Lidocaine patch for the treatment of OUD. During the projected period, such collaboration is expected to boost treatment uptake. Furthermore, increased patient participation is expected to drive worldwide Opioid Use Disorder (OUD) market growth throughout the forecast period. 

DRIVING FACTORS 

Growing Opioid Addiction Cases to Augment the OUD Market Share? 

The worldwide population is today suffering from a variety of severe and chronic ailments, including pain, cancer, cardiovascular disease, and other problems. To treat these problems, painkillers, particularly opioids, are used. Drug usage frequently leads to drug addiction in the patient. The patient is expected to have drug withdrawal symptoms as a result of their increasing reliance on these drugs and their sudden discontinuation. 

According to the National Drug Dependence Treatment Centre's (NDDTC) Magnitude of Substance Use in India report published in February 2019, the prevalence of current opioid use is 2.06%, and approximately 0.55% of Indians are expected to require help for opioid use problems (harmful use and dependence). 

On account of these factors, the likelihood that patients will experience tragic outcomes, such as death induced by an opioid overdose, rises. 

Growing Focus of Government & Non-government Institutions to Support Expansion 

Another major driving reason driving market development is the growing involvement of governmental and non-governmental organisations in raising awareness about opioid overdose and associated consequences. The number of opioid addicts has substantially grown, prompting various organisations to take a more comprehensive strategy to combating the problem. Numerous countries have increased their efforts to support patients and reduce the effects of opioid addiction. 

For example, in March 2022, the Department of Health and Human Services (HHS) announced financing for substance use treatment and prevention programmes in order to increase access to medication-assisted treatment for opioid use disorder and prevent prescription drug misuse. 

Similarly, similar programmes are expected to encourage more people suffering from opioid addiction to seek treatment. These factors are expected to have a positive impact on the worldwide market throughout the forecast period. 

RESTRAINING FACTORS 

Adverse Effects of OUD Drugs to Restrain Market Growth? 

The adverse effects of the medications used to treat opioid addiction are expected to stymie the market throughout the projected period. 

These medicines commonly cause muscular pains, vomiting, diarrhoea, bone/joint pain, respiratory difficulties, bladder discomfort, constipation, and stomach cramps. Furthermore, in severe situations of adverse medication response, the patient may suffer from depression and other psychological issues. 

The hazards connected with these pharmaceuticals have resulted in a warning from the US Food and Drug Administration, which has a negative influence on the drug class, lowering the adoption of medications in this form of treatment. 

For instance, in January 2022, the U.S. FDA warned about dental problems with buprenorphine medicines dissolved in the mouth to treat OUD and pain. Dental issues, including oral infections, cavities, tooth decay, and teeth loss can be serious and have been reported even in patients with no history of dental issues. 

Such factors might hamper the market growth during the forecast period to a certain extent. 

#Opioid Use Disorder Market #Treatment Innovations #Addiction Management Trends #Global Healthcare #Substance Abuse Solutions #Opioid Addiction #Market Insights

[pharmanucleus1]

Global Neuropathic Pain Market : Unveiling Opportunities,Trends and Treatment Advancements.

Global Neuropathic Pain Market

Global Neuropathic Pain Market, By Type (Spinal Cord Stimulation (SCS) Devices, External Peripheral Nerve Stimulation, Transcutaneous Electrical Nerve Stimulation (Tens) Devices), Product Type (Rechargeable and Non-Rechargeable), Procedure (Invasive and Non-Invasive), Technology (Transcutaneous Electrical Nerve Stimulation, Transcranial Magnetic Stimulation and Respiratory Electrical Stimulation), Modality (Stationary and Portable), Mode of Purchase (Over-the-Counter Devices and Prescription-Based Devices), Pain Type (Peripheral Neuropathy, Entrapment Neuropathy, Phantom Limb Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Post Traumatic Neuropathy, Foot Pain, Coccydynia), Indication (Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Diabetic Neuropathy, Others), End User (Hospitals, Clinics, Home Healthcare,?Ambulatory Surgical Centers?and Others), Distribution Channel (Direct Tender, Third Party Distributor and Others), Country (U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, Ireland, Rest of Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Israel And Rest Of Middle East And Africa, Brazil, Argentina And Rest of South America) Industry Trends and Forecast to 2030 

Click here for full report:

https://www.pharmanucleus.com/reports/neuropathic-pain

 Market Analysis and Insights: Global Neuropathic Pain Market 

From 2023 to 2030, the worldwide neuropathic pain market is predicted to increase at a CAGR of 9.2%. The market is being pushed by the rising prevalence of chronic pain and neuropathic pain syndromes linked to a variety of illnesses. Neuropathic pain is caused by a somatosensory system lesion or illness and affects 7-10% of the general population. Multiple causes of neuropathic pain have been identified, and its prevalence is expected to rise due to an ageing global population, an increase in diabetes mellitus, and improved cancer survival following treatment. 

The industry is also being pushed by rising R&D expenditures by major market participants in order to develop better goods. However, the market is constrained by limits associated with medical equipment, which limit product application. Furthermore, the usage of traditional medicines in emerging nations due to poor health spending and a disrupted supply chain is projected to provide a hurdle to market expansion. 

The market for neuropathic pain is classified into three categories: kind, end-user, and geography. The market is separated into two segments: peripheral and central neuropathic pain. End-user categories in the market include hospitals, clinics, home healthcare, and ambulatory surgery centres. North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa make up the market. 

The North American market is expected to lead the global neuropathic pain market throughout the projected period. This is due to the high incidence of chronic pain and neuropathic pain disorders in the region. In addition, the existence of a large number of market rivals in the area is expected to boost market growth. 

During the projection period, the Asia Pacific market is predicted to be the fastest expanding. This is related to the region's ageing population, which is increasing the prevalence of chronic pain and neuropathic pain syndromes. Furthermore, increased knowledge regarding neuropathic pain and its treatment alternatives is likely to fuel market expansion in the area. 

Click here for full report:

https://www.pharmanucleus.com/reports/neuropathic-pain

The neuropathic pain market report provides a detailed analysis of the market, including its drivers, restraints, opportunities, and challenges. The report also provides a detailed analysis of the competitive landscape of the market. The report also provides a detailed analysis of the market segments, including their growth prospects. 

The report concludes with a SWOT analysis of the market. The SWOT analysis provides a detailed analysis of the strengths, weaknesses, opportunities, and threats of the market. The report also provides a detailed analysis of the competitive landscape of the market. 

Neuropathic Pain Market Scope and Market Size 

The neuropathic pain market is segmented by type, product type, procedure, technology, modality, mode of purchase, pain type, indication, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets. 

By type 

The spinal cord stimulation (SCS) devices segment dominated the neuropathic pain market in 2023 due to the vast usage of these devices for various neuropathic pain indications and the wide range of the products available in the market. 

Click here for free sample report:

https://www.pharmanucleus.com/request-sample/1181

By product type 

The rechargeable segment is expected to show significant growth in the neuropathic pain market due to rechargeable devices avoiding the surgical replacement of the discharged battery in traditional devices. 

By procedure 

The invasive segment is expected to dominate the neuropathic pain market in 2023 because these devices available in the market are generally operating by invasive procedures that generally provide better efficiency for neuropathic pain. 

By technology 

The transcutaneous electrical nerve stimulation segment is expected to show significant growth in the neuropathic pain market due to transcutaneous electrical nerve stimulation being a non-invasive, inexpensive, self-administered technique to relieve pain. Due to the growing technological advancement, these devices are increasing their market size. 

By Modality 

The stationary devices segment is expected to show significant growth rate in the neuropathic pain market due to rising incidences of chronic diseases such as cancer, cardiovascular, neurovascular disease, and musculoskeletal diseases which generally include RF generators and other devices which are stationary in nature. 

By mode of purchase 

The prescription-based devices segment is expected to dominate the neuropathic pain market in 2023 due to the wide range of products available as prescription-based devices increase the market share of the segment. 

By pain type 

The peripheral neuropathy segment is expected to show the significant growth in the neuropathic pain market due to the increasing prevalence of peripheral neuropathy across the globe. 

By indication 

The diabetic neuropathy segment is likely to dominate the neuropathic pain market in 2023 due to the changi

#Neuropathic Pain

[pharmanucleus1]

Global Disposable Medical Sensors Market Insights : Revolutionizing Healthcare

The global disposable medical sensors market was valued at USD 9.52 billion in 2022 and is projected to grow at a CAGR of 18.45% from 2023 to 2030. This growth can be attributed to technological advancements, increasing demand for health data tracking, and the need for low-cost medical devices. The rising prevalence of chronic diseases worldwide is expected to drive the demand for disposable medical sensors. According to a report by Front. Public Health in 2020, chronic non-communicable diseases (NCDs) accounted for approximately 80% of mortality among Chinese adults aged 60, with Ischemic heart disease, stroke, Chronic Obstructive Pulmonary Disease (COPD), and Type 2 diabetes being the most common conditions. The growing adoption of disposable medical sensors in healthcare settings is likely to contribute to the market's expansion in the coming years. 

Click here for full report:

https://www.pharmanucleus.com/reports/disposable-medical-sensors

Market Insights: 

In the global disposable medical sensors market, the diagnostic segment led the market in 2022, accounting for over 39.38% of the global revenue. Disposable medical sensors are widely used in diagnostic devices such as surgical tools, endoscopy equipment, spirometry devices, and medical imaging devices, enhancing their capabilities and enabling early disease detection. Advanced sensors, such as carbon nanotube-based biosensors, are being used to detect microorganisms like S. aureus and E. coli, providing faster and more accurate results at a lower cost. The integration of wireless communication and biosensors is creating growth opportunities in the diagnostic field. 

The increasing prevalence of chronic diseases and the demand for diagnostics are driving the adoption of disposable medical sensors. Diagnostic devices are crucial for monitoring symptoms and signs of chronic diseases like diabetes. Companies are developing innovative solutions to improve diagnostic capabilities, such as portable genetic material amplification systems for point-of-care molecular diagnostic detection. The patient monitoring segment is expected to have the highest compound annual growth rate (CAGR) during the forecast period. Medical sensors are utilized in patient monitoring devices like pulse oximeters and blood pressure monitors. Advancements in technology and product launches, such as next-generation monitoring biosensors by Philips, contribute to improved quality of care. 

The demand for disposable medical sensors is projected to increase due to their various advantages, leading to a rise in R&D investments and collaborations between companies. For example, Rockley Photonics Holdings Limited and Medtronic are collaborating to implement Medtronic's solutions with Rockley's Bioptx biomarker sensing technology in healthcare settings. This collaboration aims to provide real-time, non-invasive monitoring of individuals' well-being and health, enabling proactive healthcare and personalized care based on actionable data. Such initiatives are expected to drive the growth of the patient monitoring segment in the near future. 

Click here for full report:

https://www.pharmanucleus.com/reports/disposable-medical-sensors

Product Insights: 

In 2022, the biosensors segment held the largest market share, accounting for over 49.70% of the market. Biosensors are sensors designed to detect analytes by collecting biological components and utilizing a physiochemical detector. The signals from the analyte are detected, measured, and displayed on the device through associated electronics. Various types of biosensors are used, including electronic, amperometric, blood glucose, potentiometric, conduct metric, thermometric, optical, fiber optic lactate, immune, and piezoelectric biosensors. Biosensors have applications in patient monitoring and diagnostics, and the increasing demand for rapid and accurate diagnostic kits is driving the growth of biosensors. Innovations in biosensor technology are expected to lead to the development of advanced biosensors for faster diagnosis in the future. 

The image sensors segment is projected to have the highest compound annual growth rate (CAGR) during the forecast period. Image sensors convert light waves into signals to create images and find extensive use in diagnostic devices such as endoscopy equipment and electronic imaging devices. There are two types of image sensors: charge-coupled devices (CCD) and complementary metal oxide semiconductors (CMOS). CMOS image sensors are more commonly used due to their lower power consumption and faster diagnostic speed. They are primarily utilized in x-ray imaging, minimally invasive surgery, endoscopy, and ocular surgery. Technological advancements and the demand for higher resolution are expected to drive market growth in the image sensors segment.

Click here for Free sample request:

https://www.pharmanucleus.com/request-sample/1180 

Market Segmentation: 

The strip sensors segment held the largest market share in 2022, accounting for over 38.76% of the market. Strip sensors are primarily used in blood glucose monitoring, disease testing, and magnetic nanoparticles. Their dominance in the market is attributed to increasing demand and their widespread usage in diagnostic applications. Strip sensors offer the advantage of faster results, which contributes to their popularity. Furthermore, the market is driven by the growing demand for self-diagnosis and home-based medical devices. 

The ingestible sensors segment is projected to have the highest compound annual growth rate (CAGR) during the forecast period. Ingestible sensors are small chips enclosed in capsules that are swallowed, allowing for detection of any abnormalities in the body and transmission of the data to an external device. These sensors find applications in endoscopy, controlled drug delivery, and patient monitoring. The rising prevalence of chronic diseases and the need for invasive diagnostic testing are driving the growth of ingestible sensors. Additionally, the accuracy of results obtained through ingestible sensors further fuels their demand in the market. 

Due to the various advantages of ingestible sensors, the demand for these devices is anticipated to increase during the forecast period. Increasing R&D investments and collaborations between companies are also expected to propel market growth. In July 2021, according to Medtronic plc, the FDA cleared the use of two LINQ II insertable cardiac monitors with the AI AccuRhythm algorithms. When the AI AccuRhythm algorithms are made accessible on the CareLink Network later this year, all LINQ II implants in the U.S will be able to use them. 

Regional Analysis: 

North America dominated the global disposable medical sensors market in 2022, holding the largest revenue share of over 41.18%. This can be attributed to several factors, including the region's well-established healthcare infrastructure, high healthcare spending, the presence of monopolistic market players, and the rapid adoption of cutting-edge technologies. The market in North America is highly developed and is expected to be driven by the increasing uptake of patient monitoring and homecare devices for routine, ongoing, and long-term patient monitoring, which helps reduce the frequency of hospital visits. 

Favorable reimbursement policies are expected to further fuel market expansion in North America. Additionally, the rising prevalence of lifestyle-related health issues, accidents, and sports injuries contribute to the growth potential in the region. The increasing use of mobile surgery centers and the demand for effective emergency care are also anticipated to boost the market during the forecast period. Moreover, the COVID-19 pandemic has highlighted the importance of disposable medical sensors in enabling remote patient monitoring and care at home, leading to increased adoption of these devices. 

The Asia-Pacific region is projected to experience the fastest growth in the global disposable medical sensors market during the forecast period. The region witnesses a significant demand for disposable medical sensor equipment due to the increasing prevalence of cardiac disorders, particularly in countries like China and India, which also have high diabetes rates. The rising burden of diabetes in the region is driving the demand for home-based disposable medical sensors, creating new market opportunities. Additionally, the presence of major companies in the disposable medical sensors market further contributes to the region's market share and growth potential. 

#Disposable Medical Sensors Market #Healthcare Technology #Sensor Innovations #Global Market Trends #Medical Device Industry #Sensor Solutions #Market Insights

[pharmanucleus1]

#Cyber Security #Medical Devices #Healthcare Technology #Global Market #Patient Safety #Cyber Threats #Data Protection #Digital Health #Industry Trends

[pharmanucleus1]

#CTLA-4 Therapies Market #Global Market Trends #Latest Therapeutic Advancements #Innovations in CTLA-4 Therapies #Recent Developments in Immunotherapy #Immune Checkpoint Inhibitors #Cancer Treatment Breakthroughs

[pharmanucleus1]

#Cancer Supportive Care Drugs #Supportive Care in Cancer #Cancer Treatment #Oncology Industry #Quality of Life in Cancer #Cancer Support Therapies

[pharmanucleus1]

#Bleeding disorders #treatment market #innovative therapies #industry insights #growth opportunities #market research #healthcare advancements #proffesional healthcare #bleeding disorders industry

[pharmanucleus1]

#Artificial Womb Facility #Womb Technology #Market Research #Industry Advancements #Futuristic Healthcare #Reproductive Technology #Gestational Surrogacy #Pregnancy Alternatives #Fetal Development #Maternal Health #Neonatal Care

[pharmanucleus1]

Global Cyber Security in Medical Devices Market - Safeguarding Healthcare in the Digital Age

Global Cyber Security in Medical Devices

The medical devices industry has seen a significant growth in digitization in recent years as well as cyber threats have steadily increasing day-to-day. Therefore the Cyber security is one of the vital aspects of the medical devices sector as it protects medical records, patients' personal information, lifesaving insights and healthcare information. Moreover the medical devices companies have battled to secure their valued healthcare information from cyber-attacks and data breaches. Currently, cyber security firms provide information-security services and solutions to medical devices like Medical imaging devices, implant devices and internet of medical things. 

Click here for full report:

https://www.pharmanucleus.com/reports/cyber-security-in-medical-devices

Market Dynamics

Cyber-security is a risk management strategy designed to protect software and technology, networks, devices, healthcare data and programs from data theft, digital attacks and unauthorized access. As part of it, increasing problems of cyber-attacks on medical devices in both developed and developing countries reflect growing security and regulatory compliance issues. Moreover, the increasing data breach in the industry adds fuel to the market growth for medical devices cyber security. The average cost of data breach reaches an all-time high. For instance, according to the cost of a data breach report published by IBM in 2022. The average cost of a data breach in the healthcare sector was USD XX million in 2021 and it increased by XX% in 2022. Moreover, according to CloudSEK 2021 report , increased cyber -attacks on the global healthcare sectors like medical devices and hospital sectors, the U.S. healthcare industry faced XX% of the total global attacks and globally Indian healthcare industry were 2nd largest cyber-attacks with XX % of total incidence in the segment. 

Challenges 

Medical devices are an easy entry point to attacking for cyber-attackers, therefore necessary to protect data from hackers but healthcare industries faces shortage of trained professionals to manage cyber-security solutions as well as high cost of medical devices cyber-security solutions in developed and developing regions. Moreover, these high cost cyber security services is a significant barrier to growing the healthcare cyber security market in medical devices. It reflects effects on emerging and development of information. 

Development Landscape 

Biotech and medical device manufacturer businesses are adopting both organic and inorganic growth strategies to advance their pipeline and gain competitive edge in the market over the peers. 

Cisco (US),IBM (US), GE Healthcare (US), Symantic (US), ClearPassage (US), FireEye (US), Check Point Tech (Israel), Sophos (UK), Imperva (US),Fortinet (US), ClodePassage (US), ClearData (US) and Zscaler (US) 

Regional Analysis 

North America is anticipated to capture the highest share of cyber security in medical devices market over the forecast period (2022-2027), with U.S. accounting for the maximum contribution.

Click here for full report:

https://www.pharmanucleus.com/reports/cyber-security-in-medical-devices

Increasing instances of cyber-attacks on medical devices along with increasing awareness among healthcare sector professionals regarding cyber security moreover, most number of manufacturing facilities and key players, some of the best research universities and an encouraging start-up eco system provide an ideal solution for research leading to more successful assets in pipeline.

Macro-economic factors such as large population and growing economy, highly prevalence in healthcare organizations and medical devices industries, better access to protect data security, availability of crowd funding and support from various stakeholders’ fuels US as a commercially attractable market. 

Asia-Pacific region is expected to pick up pace over the next few years due to favourable growth factors such as

The market is focusing on Asia-Pacific as a destination for outsourcing and trying to gain foothold through mergers, collaborations, and strategic acquisitions.

The global Cyber security in medical devices market estimates (Value USD Million) & Forecasts and Trend Analyses, 2022 to 2027 based on Security Type 

The Global Cyber security in medical devices Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2022 to 2027 based on Type of Threat 

Click here for free sample report:

https://www.pharmanucleus.com/request-sample/1179

The Global Cyber security in medical devices Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2022 to 2027 based on End User 

The Global Cyber security in medical devices Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2022 to 2027 based on Region 

What is Cyber security in Medical Devices Market Report about? 

The cyber security in medical devices market report discusses the commercial and clinical activity associated with cyber security in medical devices. It provides insights on total size of the potential opportunity, key segments driving growth, key challenges faced, and a thorough analysis of market competition by product, geography, indication, and forecasts through 2027. Detailed coverage of the approved cyber security in medical devices, including regulatory approvals, pricing, reimbursement, and market penetration 

So, a new investor can potentially gain information about cyber security in medical devices companies, their key products, their core strategy, key trends in the cyber security in medical devices market, and more. 

The cyber security in medical devices market report is essential for all stakeholders including research companies, manufacturing companies, distribution companies, government agencies, and others. 

#Cyber Security #Medical Devices #Healthcare Technology #Global Market #Patient Safety #Cyber Threats #Data Protection #Digital Health #Industry Trends

[pharmanucleus1]

Global CTLA-4 Therapies Market - Unveiling Cutting-Edge Insights

Global CTLA-4 Therapies Market

The global CTLA-4 Therapies market is expected to reach USD 1384.4 million by 2030, at a CAGR of 7.1% during the forecast period 2022 to 2030. The modulation of cell motility and/or PI3 kinase signaling may also be other ways that CTLA-4 works. Early multiphoton microscopy investigations to observe T-cell movement in healthy lymph nodes seemed to support the "reverse-stop signalling paradigm."

Click here for full report:

https://www.pharmanucleus.com/reports/ctla-4-therapies

Market Overview 

The protein receptor CTLA-4, also known as CD152 (cluster of differentiation 152) or CTLA4 (cytotoxic T-lymphocyte-associated protein 4), serves as an immunological checkpoint and suppresses immune responses. A characteristic that is especially noticeable in malignancies is the constitutive expression of CTLA-4 in regulatory T cells as opposed to the upregulation of this protein in conventional T cells following activation. When attached to CD80 or CD86 on the surface of antigen-presenting cells, it functions as an "off" switch. An inhibitory signal is sent to T cells by the immunoglobulin superfamily member CTLA-4, which is produced by activated T cells. Similar to the T-cell co-stimulatory protein CD28, CTLA-4 binds to antigen-presenting cells' CD80 and CD86, also known as B7-1 and B7-2, respectively. CTLA-4 outcompetes CD28 for its ligands because it binds CD80 and CD86 with greater avidity and affinities. T cells receive an inhibitory signal from CTLA-4 while receiving a stimulatory signal from CD28. Additionally present in regulatory T cells (Tregs), CTLA-4 is a component of their inhibitory activity. CTLA-4 expression is enhanced by T cell activation via the T cell receptor and CD28. It's still unclear how CTLA-4 affects T cells and how it does so. According to biochemical data, CTLA-4 attenuates the signal by bringing a phosphatase to the T cell receptor (TCR). Since this work was first published, it has not been supported by the literature. Recent research has revealed that CTLA-4 may work in vivo by engulfing and removing CD80 and CD86 from antigen-presenting cells' membranes, rendering them inactive for CD28 triggering. 

Click here for full report:

https://www.pharmanucleus.com/reports/ctla-4-therapies

Market Dynamics 

T-cell immunological activity is negatively regulated by immune checkpoints called programmed death 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). New immunotherapies for melanoma, non-small cell lung cancer, and other cancers have been developed as a result of the inhibition of these targets, which boosted immune system activation. Ipilimumab, a CTLA-4 inhibitor, is approved to treat advanced or incurable melanoma. In patients with metastatic or incurable BRAF WT melanoma, the combination of ipilimumab and nivolumab has also been authorized. Inhibiting immune responses, especially anticancer responses, play unique roles for CTLA-4. 

Mutations in the CTLA4 gene, which provides instructions to cells for producing the CTLA4 protein, are the cause of CTLA4 deficiency. The immune system's activity is slowed and controlled by this protein, which acts as a brake. The CTLA4 gene is two copies per person, one from each parent. In 2014, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) discovered that individuals with only one functional copy of CTLA4 have abnormal T-cell activity, lower levels of normal, antibody-producing B cells, higher levels of autoimmune B cells, and disruption of organs by invading immune cells. The scientists came to the conclusion that a single functional copy of CTLA4 is insufficient to generate enough CTLA4 protein for a healthy immune system. 

Request for free sample report”

https://www.pharmanucleus.com/request-sample/1178

While PD-1 suppresses T cells later in an immune response, largely in peripheral tissues, CTLA-4 is hypothesized to control T-cell proliferation early in the immunological response, primarily in lymph nodes. Due to the molecular distinctions between these 2 checkpoints, immuno-oncology drugs that block them may have different clinical characteristics. 

Intestinal sickness, respiratory infections, autoimmune issues, swollen lymph nodes, the liver, and the spleen are just a few of the symptoms caused by the rare ailment CTLA4 deficiency, which significantly inhibits the immune system's ability to regulate itself. In 2014, NIAID researchers and their associates discovered the illness. 

Segmentation Analysis: 

Based on the treatment, the CTLA-4 therapies market is categorized into autoimmune conditions and immunoglobulin deficits, and others. In 2022, the autoimmune conditions and immunoglobulin deficits segment accounted for the largest share of the market, with 59% and a market revenue of 472 million. Standard treatments for autoimmune conditions and immunoglobulin deficits may be used to treat CTLA4 deficiency. The medicine CTLA-4-Ig, also known as abatacept, which mimics the action of the CTLA4 protein and lowers immunological activity, is a potential new treatment. Abatacept is used to treat autoimmune conditions like rheumatoid arthritis, but more research is needed to determine whether it is also beneficial in treating CTLA4 deficiency. Researchers from the NIAID began a small clinical trial in 2019 to examine the efficacy and safety of intravenous infusions of abatacept for restoring or enhancing blood cell counts in persons with CTLA4 deficiency. The medication abatacept, which Bristol-Myers Squibb produces, is being given to the research. 

Based on the end-user, the CTLA-4 therapies market is categorized into?clinical & laboratories, hospitals, and others. In 2022, the clinics & laboratories segment accounted for the largest share of the market, with 40.1% and a market revenue of 320.8? million. The immune dysregulation syndrome that includes substantial T cell infiltration in a number of organs, including the gut, lungs, bone marrow, central nervous system, and kidneys, is present in symptomatic CTLA-4 mutant patients. Most patients suffer from enteropathy or diarrhea. Autoimmunity, lymphadenopathy, and hepatosplenomegaly are also frequent. Thrombocytopenia, hemolytic anemia, thyroiditis, type I diabetes, psoriasis, and arthritis are among the various organs that are impacted by autoimmunity. Additionally prevalent are respiratory illnesses. It's important to note that clinical manifestations and illness progression vary, with some people being severely impacted while others have minimal disease manifestation. Even within the same family, this "variable expressivity" can be noticeable and may be explained by variations in lifestyle, exposure to pathogens, treatment effectiveness, or additional genetic modifiers. 

Regional Segment Analysis of the CTLA-4 Therapies Market 

Asia Pacific emerged as the largest market for the global CTLA-4 Therapies market, with a market share of around 39% and 800 million of the market revenue in 2022. 

Competitive Landscape 

The report offers the appropriate analysis of the key organizations/companies involved within the global CTLA-4 Therapies market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the companies' current news and developments, including product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the mark

#CTLA-4 Therapies Market #Global Market Trends #Latest Therapeutic Advancements #Innovations in CTLA-4 Therapies #Recent Developments in Immunotherapy #Immune Checkpoint Inhibitors #Cancer Treatment Breakthroughs